All In Biotech

NDA 018553 · Ani Pharms

Inderal La

Propranolol Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Apr 19, 1983

Approved uses

4

Original approval plus efficacy supplements

Registered trials

392

63 Phase 3, 46 recruiting

FAERS reports

20,561

14,089 serious, 2,107 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

INDICATIONS AND USAGE Hypertension Propranolol hydrochloride extended-release capsules USP are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules USP are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules USP are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Migraine Propranolol hydrochloride extended-release capsules USP are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Hypertrophic Subaortic Stenosis Propranolol hydrochloride extended-release capsules USP improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Mechanism: Mechanism of Action The mechanism of the antihypertensive effect of propranolol has not been established. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 18, 1987 Supplement 13 · Efficacy Review
  • Aug 20, 1985 Supplement 8 · Efficacy
  • Jan 9, 1984 Supplement 1 · Efficacy
  • Apr 19, 1983 Original approval · Type 3 - New Dosage Form
4 products under this application
  • INDERAL LA · PROPRANOLOL HYDROCHLORIDE 60MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INDERAL LA · PROPRANOLOL HYDROCHLORIDE 80MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INDERAL LA · PROPRANOLOL HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INDERAL LA · PROPRANOLOL HYDROCHLORIDE 160MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Propranolol" as an intervention, any sponsor and status, largest first.

All 392 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,090
  • drug ineffective1,819
  • nausea1,590
  • fatigue1,370
  • headache1,334
  • diarrhoea1,061
  • dyspnoea1,018
  • dizziness1,016
  • product use in unapproved indication956
  • product use issue922
  • pain870
  • vomiting856

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004466
2005575
2006536
2007447
2008381
2009530
2010642
2011623
2012730
2013577
2014601
2015833
2016886
2017741
2018865
2019936
2020917
20211,165
20221,575
20231,731
20242,098
20251,483
20261,222

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inderal La (Propranolol HCl)

2024 spending

$7.2M

Beneficiaries

261

1,324 claims

Per beneficiary

$27,694

$71.25 per unit

View as table
YearSpending
2020$12,790,625
2021$11,435,127
2022$9,453,606
2023$8,234,374
2024$7,228,104

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,505 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.